Syndax Pharmaceuticals (SNDX) Net Cash Flow Growth (3y) (2018 - 2026)
Syndax Pharmaceuticals (SNDX) Net Cash Flow Growth (3y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,184.45 Bn | 68,184.17 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 474.39 Bn | 469.59 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.21 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 63.43 Bn | 63.43 Bn | - | - |
| 8 | Argenx Se | 56.67 Bn | 51.49 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 38.08 Bn | 38.08 Bn | - | - |
| 10 | Syndax Pharmaceuticals | 1.88 Bn | 1.53 Bn | 53.02 Mn | 37.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.88% |
| Dec 31, 2025 | 82.16% |
| Sep 30, 2025 | 29.41% |
| Jun 30, 2025 | 12.85% |
| Mar 31, 2025 | 86.06% |
| Dec 31, 2024 | -48.08% |
| Sep 30, 2024 | 101.19% |
| Jun 30, 2024 | -65.37% |
| Mar 31, 2024 | -52.62% |
| Dec 31, 2023 | 50.53% |
| Sep 30, 2023 | -44.11% |
| Jun 30, 2023 | 64.33% |
| Mar 31, 2023 | -41.63% |
| Dec 31, 2022 | 35.55% |
| Sep 30, 2022 | -143.74% |
| Jun 30, 2022 | -29.65% |
| Mar 31, 2022 | -49.83% |
| Dec 31, 2021 | 177.24% |
| Sep 30, 2021 | 37.80% |
| Jun 30, 2021 | -4.71% |